Phase II Clinical Trial of Pazopanib to evaluate the activity and tolerability in patients with advanced and/or metastatic liposarcoma who have relapsed following standard therapies or for whom no standard therapy exists

Trial Profile

Phase II Clinical Trial of Pazopanib to evaluate the activity and tolerability in patients with advanced and/or metastatic liposarcoma who have relapsed following standard therapies or for whom no standard therapy exists

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Liposarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2018 The study has been completed in Spain (End date: 2018-03-02)
    • 02 Mar 2018 This trial has been completed in Germany (end date: 2017-12-13).
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top